Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1993 3
1994 4
1995 3
1996 5
1997 1
1998 4
1999 3
2000 8
2001 5
2002 7
2003 3
2004 6
2005 2
2006 6
2007 4
2008 13
2009 10
2010 10
2011 8
2012 8
2013 4
2014 3
2015 6
2016 1
2018 1
2019 4
2020 3
2021 4
2022 6
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: piketty c. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, Bieber T, Misery L, Wollenberg A, Reich A, Ahmad F, Piketty C. Ständer S, et al. Among authors: piketty c. N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316. N Engl J Med. 2020. PMID: 32074418 Clinical Trial.
Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xing X, Patrick MT, Billi AC, Berthier CC, Kahlenberg JM, Lazzari A, Wiegmann H, Ständer S, Piketty C, Julia V, Krishnaswamy JK, Gudjonsson JE. Tsoi LC, et al. Among authors: piketty c. J Allergy Clin Immunol. 2022 Apr;149(4):1329-1339. doi: 10.1016/j.jaci.2021.10.004. Epub 2021 Nov 29. J Allergy Clin Immunol. 2022. PMID: 34857395 Free PMC article.
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Silverberg JI, et al. Among authors: piketty c. J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23. J Allergy Clin Immunol. 2020. PMID: 31449914 Free article. Clinical Trial.
Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
Ma F, Gharaee-Kermani M, Tsoi LC, Plazyo O, Chaskar P, Harms P, Patrick MT, Xing X, Hile G, Piketty C, Lazzari A, Van Delm W, Maverakis E, Nakamura M, Modlin RL, Kahlenberg JM, Billi AC, Julia V, Krishnaswamy JK, Gudjonsson JE. Ma F, et al. Among authors: piketty c. J Allergy Clin Immunol. 2024 Jan;153(1):146-160. doi: 10.1016/j.jaci.2023.07.005. Epub 2023 Jul 26. J Allergy Clin Immunol. 2024. PMID: 37506977 Free article.
Patient Perspectives on Living With Severe Prurigo Nodularis.
Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C, Puelles J. Rodriguez D, et al. Among authors: piketty c. JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251. JAMA Dermatol. 2023. PMID: 37728897 Free PMC article.
Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis.
Wagner N, Loprete L, Duval V, Jauslin P, Benkali K, Silverberg JI, Wollenberg A, Saito T, Ahmad F, Graeber M, Winkelman W, Piketty C. Wagner N, et al. Among authors: piketty c. J Drugs Dermatol. 2023 Oct 1;22(10):1017-1020. doi: 10.36849/JDD.7437R1. J Drugs Dermatol. 2023. PMID: 37801534
148 results